Key terms

About IGC

IGC Pharma, Inc. engages in the development and commercialization of cannabinoid based alternative therapies for indications, such as Alzheimer's disease, Parkinson's disease, and pain. The firm is involved in researching the application of cannabinoids, such as Tetrahydrocannabinol and Cannabidiol in combination with other compounds to address various ailments, including Alzheimer's disease. It operates through the Infrastructure Business and Life Sciences segments. The Infrastructure Business segment is involved in the rental of heavy construction equipment, execution of construction contracts, and purchase and resale of physical commodities used in infrastructure. The Life Sciences segment includes a biotech component, and a vertically integrated hemp-cannabinoid based healthcare and wellness business, which involves the production of plant and cannabinoid-based products, and therapies. The company was founded by Ram Mukunda on April 29, 2005 and is headquartered in Potomac, MD.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest IGC news

Apr 16 7:06am ET IGC Pharma: Trial data show reduction in Alzheimer’s agitation at week two Apr 11 10:24am ET Here’s What You Missed in Cannabis, Psychedelics This Week Apr 05 11:42am ET India Globalization Capital: Breakthrough in Alzheimer’s Treatment Trial Apr 04 11:06am ET Here’s What You Missed in Cannabis, Psychedelics This Week Apr 01 4:29pm ET Supreme Court of Florida approves marijuana measure for November ballot Mar 28 11:32am ET Rising High: Exclusive talk with financial services firm Safe Harbor Financial Mar 26 3:02pm ET IGC Pharma announces $3M unregistered private placement of common stock Mar 22 10:56am ET Cannabis stocks rally after Germany passes partial legalization law Mar 21 10:52am ET Here’s What You Missed in Cannabis, Psychedelics This Week Mar 20 11:25am ET India Globalization Capital trading resumes Mar 20 11:03am ET IGC Pharma reports ongoing Phase 2 AAD trial achieves primary end point Mar 20 10:15am ET India Globalization Capital trading halted, news pending Mar 14 11:15am ET Rising High: Exclusive talk with cannabis market research firm BDSA Mar 13 9:12am ET India Globalization Capital Welcomes New Board Member Mar 07 1:09pm ET Rising High: Exclusive talk with multi-state operator C3 Industries Mar 07 10:46am ET Rising High: Exclusive talk with vape tech developer Ispire Technology Feb 29 11:29am ET Here’s What You Missed in Cannabis, Psychedelics This Week Feb 29 11:29am ET Here’s What You Missed in Cannabis, Psychedelics This Week Feb 28 1:01pm ET IGC Pharma data for TGR-63 enhances memory function in Alzheimer’s mouse model Feb 22 11:19am ET Here’s What You Missed in Cannabis, Psychedelics This Week Feb 22 11:19am ET Here’s What You Missed in Cannabis, Psychedelics This Week Feb 15 10:57am ET Rising High: Exclusive talk with cannabis market research firm BDSA Feb 15 10:57am ET Rising High: Exclusive talk with cannabis market research firm BDSA Feb 12 5:24am ET IGC Pharma initiated with a Buy at Ascendiant Feb 12 5:05am ET Buy Rating Justified by India Globalization Capital’s Promising Alzheimer’s Treatment Pipeline and Market Potential Feb 12 5:02am ET Analysts Offer Insights on Healthcare Companies: India Globalization Capital (IGC), Tango Therapeutics (TNGX) and Teva Pharmaceutical (TEVA) Feb 08 11:22am ET Rising High: Exclusive talk with house of brands Carma HoldCo Feb 08 11:22am ET Rising High: Exclusive talk with house of brands Carma HoldCo Feb 01 11:35am ET Rising High: Exclusive talk with drug manufacturer Optimi Health Feb 01 11:35am ET Rising High: Exclusive talk with drug manufacturer Optimi Health Feb 01 11:21am ET Rising High: Exclusive talk with drug manufacturer Optimi Health

IGC Financials

1-year income & revenue

Key terms

IGC Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

IGC Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms